GoAI
Get started
Palatin Technologies, Inc. logo

Palatin Technologies, Inc.

PTN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$9.69

−$0.51 · -5.00%

Aug 21, 4:00 PM ET

PTN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

39

Expensive

Momentum

21

Weakening

Sentiment

62

Bullish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Carl Spana
Listed since
Oct 15, 1997
Employees
29

Market position

Day range

Current $9.69

52-week range

Current $9.69

Open
$10.63
Previous close
$10.20
Volume
4.5K
0.26× average
Average volume
17.26K
Average daily volume
Market cap
17.24M USD
Beta
-0.07
Market reference 1
50-day average
$9.7114
-0.22% below average
200-day average
$15.9514
-39.25% below average

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends19828%11712%3596%-4521%Gross margin, FY2021: 178.39%Gross margin, FY2022: 85.19%Gross margin, FY2023: 91.38%Gross margin, FY2024: 97.83%Operating margin, FY2021: 17701.29%Operating margin, FY2022: -2491.63%Operating margin, FY2023: -668.75%Operating margin, FY2024: -501.02%Net margin, FY2021: 17799.23%Net margin, FY2022: -2465.06%Net margin, FY2023: -495.23%Net margin, FY2024: -662.26%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 178.39%. Gross margin FY2022 85.19%. Gross margin FY2023 91.38%. Gross margin FY2024 97.83%. Operating margin FY2021 17701.29%. Operating margin FY2022 -2491.63%. Operating margin FY2023 -668.75%. Operating margin FY2024 -501.02%. Net margin FY2021 17799.23%. Net margin FY2022 -2465.06%. Net margin FY2023 -495.23%. Net margin FY2024 -662.26%.

Income trends

Revenue

4.49M USD-7.49%

Operating income

−17.46M USD+22.39%

Net income

−17.31M USD+41.80%
Income trends across reported periods9M USD−7.58M USD−24.16M USD−40.73M USDRevenue, FY2021: −188.6K USDRevenue, FY2022: 1.47M USDRevenue, FY2023: 4.85M USDRevenue, FY2024: 4.49M USDOperating income, FY2021: −33.38M USDOperating income, FY2022: −36.59M USDOperating income, FY2023: −32.46M USDOperating income, FY2024: −22.5M USDOperating income, FY2025: −17.46M USDNet income, FY2021: −33.57M USDNet income, FY2022: −36.2M USDNet income, FY2023: −24.04M USDNet income, FY2024: −29.74M USDNet income, FY2025: −17.31M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 −188.6K USD. Revenue FY2022 1.47M USD. Revenue FY2023 4.85M USD. Revenue FY2024 4.49M USD. Operating income FY2021 −33.38M USD. Operating income FY2022 −36.59M USD. Operating income FY2023 −32.46M USD. Operating income FY2024 −22.5M USD. Operating income FY2025 −17.46M USD. Net income FY2021 −33.57M USD. Net income FY2022 −36.2M USD. Net income FY2023 −24.04M USD. Net income FY2024 −29.74M USD. Net income FY2025 −17.31M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—4.49M USD4.85M USD1.47M USD−188.6K USD
Cost of goods sold—97.64K USD418.47K USD217.53K USD147.84K USD
Gross profit—4.39M USD4.44M USD1.25M USD−336.44K USD
Research and development14.9M USD22.4M USD22.63M USD21.33M USD12.93M USD
Selling, general, and administrative7.81M USD12.27M USD15.29M USD16.51M USD17.34M USD
Operating expenses17.46M USD26.89M USD36.89M USD37.84M USD33.05M USD
Interest income————23.57K USD
Interest expense15.03K USD17.11K USD20.01K USD29.68K USD—
Depreciation and amortization258.92K USD339.08K USD288.33K USD486.02K USD51.12K USD
Operating income−17.46M USD−22.5M USD−32.46M USD−36.59M USD−33.38M USD
Net income−17.31M USD−29.74M USD−24.04M USD−36.2M USD−33.57M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
50%
5 beats, 5 misses, 0 met estimates
Average EPS surprise
-363.93%
10 comparable reports
Latest EPS result
-0.37
Estimate -1.24 · Beat by 70.24%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates6.64-4.87-16.37-27.88Q4 '24BeatQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25No estimateQ1 '26MissQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Nov 14, 2024: actual -19.5, estimate -25.5, surprise +23.53%, Beat. Q1 2025, reported Feb 13, 2025: actual -6, estimate -21, surprise +71.43%, Beat. Q2 2025, reported May 14, 2025: actual -9, estimate -8.5, surprise -5.88%, Miss. Q3 2025, reported Sep 23, 2025: actual -3.43, estimate -9.5, surprise +63.89%, Beat. Q4 2025, reported Nov 14, 2025: actual 4.26, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 17, 2026: actual -2.86, estimate -2.35, surprise -21.53%, Miss. Q2 2026, reported May 13, 2026: actual -0.37, estimate -1.24, surprise +70.24%, Beat. Q3 2026, reported Sep 2, 2026: actual —, estimate -1.2, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates9.55M6.38M3.2M21.25KQ4 '24EstimateQ1 '25EstimateQ2 '25EstimateQ3 '25EstimateQ4 '25No estimateQ1 '26BeatQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Nov 14, 2024: actual —, estimate 314K USD, surprise —, Comparison unavailable. Q1 2025, reported Feb 13, 2025: actual —, estimate 346K USD, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual —, estimate 7.88M USD, surprise —, Comparison unavailable. Q3 2025, reported Sep 23, 2025: actual —, estimate 7.5M USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual 8.85M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 17, 2026: actual 116.04K USD, estimate 25K USD, surprise +364.14%, Beat. Q2 2026, reported May 13, 2026: actual 3.92M USD, estimate 1.28M USD, surprise +205.53%, Beat. Q3 2026, reported Sep 2, 2026: actual —, estimate 1.5M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

PTN news

PTN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PTN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
145.61K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
56.09K
Weight
0.00%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research PTN

research.disclaimer